Featured Research

from universities, journals, and other organizations

Electric field propels worms to test new drugs

Date:
January 6, 2010
Source:
McMaster University
Summary:
Researchers have developed a way to view the effects of a proposed drug treatment in real time using a mild electrical field to stimulate C. elegans nematodes. The discovery opens up significant possibilities for developing high-throughput micro-screening devices for drug discovery and other applications for treating diseases such as Huntington's, Parkinson's and muscular dystrophy.

(a) The application of +8 V cm-1 electric field (E) caused an animal (724 m long) to move with the speed of 308 m s-1 to the right towards the cathode. (b) At a lower field strength in a reverse direction (-3 V cm-1) the animal (847.5 m long) moved with a speed of 342 m s-1 to the left towards the cathode. Dark thick arrows illustrate the worm's position. Scale bars are 1 mm.
Credit: McMaster University

A Nobel-winning process for testing new drugs to treat diseases such as Huntington's, Parkinson's, and muscular dystrophy is getting an electrical charge.

Researchers at McMaster University have developed a way to propel and direct microscopic-sized worms (C. elegans nematodes) along a narrow channel using a mild electric field. The discovery opens up significant possibilities for developing high-throughput micro-screening devices for drug discovery and other applications.

"This is the first time that worms have been stimulated to move in a micro-channel device in a very precise and directed way," said Bhagwati Gupta, assistant professor of biology. "It will allow researchers to study in real time how a proposed drug affects neurons and muscles that control motion of a live specimen."

The research is described in the January 21, 2010 issue of Lab on a Chip, a leading international journal in the field of nanotechnology and bioengineering. The researchers demonstrate movement of the worms forward and in reverse inside a microchannel, guided by the direction of the electric field (electrotaxis).

"The electrotaxis of the worms has the potential to automate what is currently a slow, manual process for drug screening on worms," said Ravi Selvaganapathy, assistant professor of mechanical engineering. "The system is fairly easy and inexpensive to scale up to conduct rapid screening of tens of thousands of chemicals in worms to identify drug candidates in a cost-effective manner. Such discovery could accelerate clinical trials in people by allowing scientists to focus only on relevant drugs and would use limited resources more efficiently."

Currently, researchers observe worms individually under a microscope as they move in a random manner or in a direction forced by pressure. The new development retains a worm's natural motion and causes no harm to the worm.

A surprising observation was that the response of the worms was dependent on its age and neuronal development. This allows for large numbers of worms to be sorted and handled in an automated manner.

The findings promise to impact other research areas as well. It will allow researchers to study how neurons respond to electricity. It can also be used to fabricate new kinds of devices to handle and manipulate large numbers of worms.

The use of C. elegans as a genetic model organism was first undertaken by Sydney Brenner in 1974. He was presented with the Nobel Prize in Physiology or Medicine in 2002 for his work in this area. Researchers working with C. elegans were also awarded Nobel prizes in 2006 and 2008.

C. elegans is a proven animal model for the study of human diseases because it utilizes many of the same proteins and molecules as humans. It also has a generation time of approximately only four days and a lifespan of about two to three weeks. This accelerates the understanding of the function of disease-related proteins.


Story Source:

The above story is based on materials provided by McMaster University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Pouya Rezai, Asad Siddiqui, Ponnambalam Ravi Selvaganapathy and Bhagwati P. Gupta. Electrotaxis of Caenorhabditis elegans in a microfluidic environment. Lab on a Chip, 2010; 10 (2): 220 DOI: 10.1039/b917486a

Cite This Page:

McMaster University. "Electric field propels worms to test new drugs." ScienceDaily. ScienceDaily, 6 January 2010. <www.sciencedaily.com/releases/2010/01/100105150650.htm>.
McMaster University. (2010, January 6). Electric field propels worms to test new drugs. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/01/100105150650.htm
McMaster University. "Electric field propels worms to test new drugs." ScienceDaily. www.sciencedaily.com/releases/2010/01/100105150650.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins